Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia

Phase 2

Completed

• Conditions: Severe preeclampsia; Preeclampsia

• Registration Number: TCTR20221014007
• Lead Sponsor: ocal, in Arifin Achmad Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2022-04-20
• Study Start: 2022-10-14
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

All pregnant women with a diagnosis of severe preeclampsia. Gestational age of 28 to 34 weeks. Live fetus. Upper arm circumference 23.5 to 33 cm. Willing to participate in research. Hemoglobin level 10.5 g/dl.

Exclusion Criteria

1. Pregnant women with severe preeclampsia with decreased consciousness. 2. Pregnant women with severe preeclampsia accompanied by complications/complications such as eclampsia, HELLP syndrome, kidney failure, or acute pulmonary oedema. 3. Pregnant women with severe preeclampsia in labor. 4. Pregnant women with severe preeclampsia who received antihypertensive therapy in the last 12 hours. 5. Pregnant women with severe preeclampsia who have a history of allergy to the trial drug. 6. Pregnant women with severe preeclampsia who have a history of asthma and heart disease.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood pressure 6 hours Direct assessment

Secondary Outcome Measures

Name	Time	Method
Subjective side effect 6 hours Interview